Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)
Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)
The primary objectives of the study were to prospectively record and analyze birth defects
 and spontaneous fetal losses in women with multiple sclerosis (MS) exposed to Avonex within
 approximately 1 week of conception or during the first trimester of pregnancy, where the
 outcome of the pregnancy was unknown prospectively and to prospectively record and analyze
 pregnancy outcomes in an exploratory fashion of women with MS who stopped therapy, but who
 may have been exposed to Avonex with approximately 1 week of conception or during the first
 trimester of pregnancy.
Key Inclusion Criteria:

 -  Have been exposed to AVONEX within approximately 1 week of conception or during the
 first trimester of pregnancy.

 -  Provide sufficient information to determine that the pregnancy is prospectively
 registered (i.e., the outcome of pregnancy must be unknown prospectively).

 -  Provide verbal consent to participate in the Registry.

 -  Verbally provide contact information for herself, her HCP, and the infant's HCP (if
 applicable).

 NOTE: Other protocol defined inclusion/exclusion criteria may apply.